Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:conditionStudied |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:contrastsWith |
platinum-based chemotherapy
|
| gptkbp:endPoint |
overall survival
|
| gptkbp:enrollment |
over 1700 patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
CheckMate 227
|
| gptkbp:location |
international
|
| gptkbp:period |
Phase 3
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
improved overall survival with nivolumab plus ipilimumab
|
| gptkbp:sponsor |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:startYear |
2016
|
| gptkbp:studiedDrug |
gptkb:ipilimumab
gptkb:nivolumab |
| gptkbp:trialID |
gptkb:NCT02477826
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|